Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auxora in Critical COVID-19 Pneumonia
NCT04661540Phase 2Terminated
- Sponsor
- CalciMedica
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in COVID-19 pneumonia comparing Auxora with Placebo (2 arms). Primary endpoint: Change From Baseline in Combined CD4, CD8, and Monocyte Cell Population in BAL Fluid, as a Percent of Total WBC Population at 120 hours. Started Mar 2021; status: terminated.
02
Drugs
Auxora
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04661540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661540.